I’m 64 (okay, I’ll be 65 in a week or so), I had been feeling more fatigued than normal, and have had a dry, non-productive cough since probably January. Free community COVID-19 testing sites had been set up throughout the Atlanta area, with one close to me at Kennesaw State University. So I decided to see if I could get tested.
The way forward for tracking the second wave? No, you aren’t dreaming this and you didn’t misread. Turns out wastewater treatment labs may have an important part to play in keeping tabs on the 2019 novel coronavirus as we look to reopen America — in fact, the entire world. Authorities will want to be aware of any rise in cases, especially by region. But how can wastewater laboratories help?
Integrating Laboratory Instruments with Waters Empower 3 is a crucial initiative in many labs. Modern analytical laboratories have experienced massive growth in data volumes over the last decade. In order to meet the challenge of turning this data into knowledge, laboratories are looking to automate and integrate laboratory operations and processes as much as possible in order to enhance data integrity and provide digital continuity throughout the product lifecycle.
If you’re looking for a complete precision medicine solution for managing samples, processes, data, and analysis, look no further. We are (it can be something else, but something is needed to form the sentence)Introducing SCC’s Research Information  Systems Suite, offering an advanced workflow-processing center for genetics, genomics, proteomics, sequencing, and other lab experiments and tests.
SCC Soft Computer is a privately held company founded in 1979 by Gilbert Hakim, SCC Soft Computer is one of the leading and most widely recognized providers of clinical information management systems for the healthcare industry and is at the forefront of laboratory, genetics, blood services, and outreach information systems software development. SCC Soft Computer offers full suites of integrated laboratory and genetics information management system solutions that enable our clients to optimize their workflows and increase productivity.
What role can labs play in helping to meet the suddenly very relevant federal law recently re-authorized as the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAIA), Public Law №116–22? As we all continue to navigate through the unfamiliar waters of global lockdown, wearing of masks, gloves and other PPE, authorities are recognizing three main keys to successful pandemic prevention and management.
The latest edition of the longtime industry reference guide to systems, vendors, information and resources concerning laboratory data management has been made available to the public.
The National Institutes of Health (NIH) is our nation’s medical research agency and strives to make scientific discoveries that improve health and save lives. Founded in 1870, the NIH conducts its own scientific research through its Intramural Research Program (IRP), which supports approximately 1,200 principal investigators and more than 4,000 postdoctoral fellows conducting basic, translational and clinical research. In this blog, we will highlight recent ground-breaking NIH research.
We are thrilled to announce Benchling Insights, a new solution for life science R&D companies to make faster, more informed decisions from their data. Insights is seamlessly integrated with all Benchling applications, and enables users to query, visualize, and collaborate around high quality, structured data that resides on the platform.
Benchling enables the creation of higher quality data through a unified data model. Now, with Insights, our customers have the tools to make faster, more informed decisions about their scientific pipeline and operational processes, ultimately accelerating the pace of their research. Best of all, this product is automatically included in subscriptions to the Benchling Professional and Benchling Enterprise editions.
As part of its mission to ensure public safety, the FDA inspects manufacturers or processors of FDA-regulated products to verify that they comply with relevant regulations. The FDA also inspects facilities that conduct clinical trials with humans and laboratories that conduct studies with animals or microorganisms when these studies are used to apply for FDA approval of a medical product. A typical inspection can last for 2-3 days and involves a number of key steps that you should be aware of.
No more validation.
CSV is a thing of the past.
These are just some of the attention-grabbing headlines I’ve seen in various blogs and LinkedIn posts over the last 12 months about Computer System Assurance (CSA), and the reality couldn’t be more different.
The U.S. FDA originally targeted theirÂ
Case for Quality initiative (2011) at improving medical device quality and usability for patient safety. More recently, FDA’s Center for Devices and Radiological Health has sponsored an industry pilot team under the CSA title to improve Computer System Validation (CSV) approaches, as the existing practices were identified as a barrier to the adoption of new technologies.
But, really, how much difference can there be between Validation and Assurance?
With COVID-19 forcing many companies into undergoing a rapid and often premature digital transformation this can raise challenges for the business units.
In the laboratory it is almost impossible to perform all work remotely and we have seen multiple strategies such as rotating shifts to avoid infection and those who can work from home do so.
One of the main enabling factors is having the right laboratory informatics, LIMS, ELN and supporting infrastructure.
Colles Price, M.S., PhD is a Research Fellow in Medicine at Dana Farber Cancer Institute, Harvard Medical School, and a Postdoctoral Scholar, Cancer Program, Broad Institute. He is currently identifying and validating targets from the Cancer Dependency Map. In particular, he is interested in understanding the anti-cancer effects of hypoxia-related genes and how polar-related genes control cell proliferation and viability. We had the chance to sit down with him and learn about how COVID-19 is affecting his research.
As an industry that relies on having employees in the lab, biotech has been disrupted by COVID-19 and the dramatic and unexpected set of changes it has introduced. For many scientists, working remotely is a brand new concept. And yet, the scientific industry is also being called upon to develop tests, therapies, and vaccines that put this crisis to rest.
To share how biotechs around the world are managing their projects, caring for their people, and supporting the community during coronavirus, we built a guide with best practices and unique ideas from our customers.
TheÂ
coronavirus pandemic has now reached nearly every country in the world, with cases being confirmed in more than 200 countries and territories.Â
As of April 10th, 2020, there have been over 1.6 million cases reported globally. The actual numbers of cases are believed to be much higher due to testing shortages, unreported cases, and suspicions that some countries have not been accurately reporting the scope of their outbreaks.
With COVID-19 continuing to spread across the globe, many pharmaceutical and biotechnology companies are racing to develop vaccines and effective therapeutics to address the pandemic. As the premier laboratory informatics service provider for the life science industry, Astrix Technology Group is proud to support many of the companies on the front lines in this effort. In this blog, we will highlight some of the groundbreaking work being done right now by our customers to combat COVID-19.
The novel coronavirus has had sweeping effects on the world at large since its emergence last winter, and it will no doubt continue to affect and change the world we live in. As we do our part to shelter-in-place and practice social distancing, there are leagues of scientists and researchers working around the clock on therapeutics to treat patients infected with SARS-CoV 2.
This article is the second in a three-part series covering the response of biotech companies to the COVID-19 crisis. The first article in this series is:Â How biotechs are racing to develop COVID-19 tests.
We are living in unprecedented times right now with the recent outbreak of SAR-CoV-2 and the global emergence of the COVID-19 pandemic. And now, as never before, our nation’s attention is focused on laboratories and the diagnostic industry at large.Â
The quality of diagnostic testing during this time of international crisis will be talked about for years to come. Fortunately, many companies have joined the fight to help facilitate COVID-19 testing, as laboratories quickly ramp up to add this to their testing menu. Yet, while many of the news headlines focus on instrument manufacturers and new testing techniques, one element that is often overlooked is the critical role of a laboratory’s LIMS.
The novel SARS-CoV-2 virus and the disease it causes (COVID-19) are sweeping the world. The US’s ability to rapidly and accurately test patients, not to mention their health care providers, is critical to containing the virus. That said, it has proved to be one of the biggest challenges for our country in recent weeks.
This article is the first in a three-part series covering the response of biotech companies to the COVID-19 crisis. The second article in this series is:Â How biotechs are racing to develop COVID-19 treatments.
When it comes to managing aÂ
clinical laboratory service, getting procedures done on time and accurately is only part of the total equation. After health records have been acquired, tests have been run, and results compiled, someone has to pay for the work performed. In the modern health care landscape, executing billing practices correctly might be more time-consuming and labor-intensive than any other part of the job. But when laboratories can easily interface with their billing systems directly from their laboratory information management system, it’s possible to gain greater efficiency and incredible cost savings.
The National Institutes of Health (NIH) is our nation’s medical research agency and strives to make scientific discoveries that improve health and save lives. Founded in 1870, the NIH conducts its own scientific research through its Intramural Research Program (IRP), which supports approximately 1,200 principal investigators and more than 4,000 postdoctoral fellows conducting basic, translational and clinical research. In this blog, we will highlight recent ground-breaking NIH research.
